How NovoBioJect works: low-dose novobiocin blocks the ABCG2 pump that clears methotrexate from immune cells. More methotrexate stays inside the cells, where it can be converted to its active long-chain form. NovoBioJect is an investigational therapy and has not been approved by any regulatory authority.
How NovoBioJect works: low-dose novobiocin blocks the ABCG2 pump that clears methotrexate from immune cells. More methotrexate stays inside the cells, where it can be converted to its active long-chain form. NovoBioJect is an investigational therapy and has not been approved by any regulatory authority.